Clinical trial
A Multicenter,Randomized, Placebo-Controlled, and Double-blind Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Aged 18-45 Years
NCT05584332 is registered in ClinicalTrials.gov with Shanghai Bovax Biotechnology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter,Randomized, Placebo-Controlled, and Double-blind Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Aged 18-45 Years
- Lead sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- December 9, 2022
- Completion date
- March 23, 2023
- Enrollment
- 3,131 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ais, cervical cancer, cin1, cin2, cin3, genital wart, vain - vaginal intraepithelial neoplasia 2, vain i, vain iii, vin i, vin ii, vin iii